OPK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
OPKO Health Inc (OPK) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company is facing significant financial challenges, and while hedge funds are buying, the lack of positive news, weak financial performance, and bearish technical indicators suggest caution. It is better to hold off on investing in this stock until there are clearer signs of recovery or growth.
The MACD is slightly positive and expanding, but RSI is neutral at 51.16, indicating no clear momentum. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 1.162, with resistance at 1.208 and support at 1.116. Overall, the technical indicators suggest a bearish trend.
Hedge funds are significantly increasing their positions in OPK, with a 1498.79% increase in buying over the last quarter. Additionally, the stock has a 70% chance of gaining 2.28% in the next month.
The company's financial performance in Q4 2025 was poor, with revenue down 19.16% YoY, net income down 322.83% YoY, and EPS dropping by 300%. Gross margin also declined by 13.51%. Analysts have lowered the price target from $2.25 to $1.50, citing concerns about the sustainability of the company's performance. There is no recent news or significant insider activity to indicate a turnaround.
In Q4 2025, OPKO Health reported a revenue decline of 19.16% YoY to $148.45M, net income dropped by 322.83% YoY to -$31.26M, and EPS fell by 300% YoY to -$0.04. Gross margin also decreased to 30.29%, down 13.51% YoY. The financials indicate significant challenges for the company.
Barrington has lowered the price target from $2.25 to $1.50, maintaining an Outperform rating but expressing concerns about the sustainability of the company's performance, which relied heavily on 'other revenue' to achieve better-than-expected Q4 results.
